Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan 12;15(1):270-9.
doi: 10.3390/molecules15010270.

Synthesis and vasorelaxant and platelet antiaggregatory activities of a new series of 6-halo-3-phenylcoumarins

Elías Quezada  1 , Giovanna Delogu, Carmen Picciau, Lourdes Santana, Gianni Podda, Fernanda Borges, Verónica García-Morales, Dolores Viña, Francisco Orallo
Affiliations

Synthesis and vasorelaxant and platelet antiaggregatory activities of a new series of 6-halo-3-phenylcoumarins

Elías Quezada et al. Molecules. .

Abstract

A series of 6-halo-3-hydroxyphenylcoumarins (resveratrol-coumarins hybrid derivatives) was synthesized in good yields by a Perkin reaction followed by hydrolysis. The new compounds were evaluated for their vasorelaxant activity in intact rat aorta rings pre-contracted with phenylephrine (PE), as well as for their inhibitory effects on platelet aggregation induced by thrombin in washed human platelets. These compounds concentration-dependently relaxed vascular smooth muscle and some of them showed a platelet antiaggregatory activity that was up to thirty times higher than that shown by trans-resveratrol and some other previously synthesized derivatives.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures of trans-resveratrol, carbochromen, and warfarin.
Scheme 1
Scheme 1
General synthetic route to obtain compounds 6-17.
See this image and copyright information in PMC

References

    1. Borges F., Roleira F., Milhazes N., Santana L., Uriarte E. Simple coumarins and analogues in medicinal chemistry: Occurrence, synthesis and biological activity. Curr. Med. Chem. 2005;12:887–916. doi: 10.2174/0929867053507315. - DOI - PubMed
    1. Fiedler V.B., Scholtholt J. Effects of carbocromene on myocardial oxygen consumption in isolated dog hearts. J. Pharmacol. Exp. Ther. 1981;217:306–313. - PubMed
    1. Opherk D., Schuler G., Waas W., Dietz R., Kubler W. Intravenous carbochromen: A potent and effective drug for estimation of coronary dilatory capacity. Eur. Heart J. 1990;11:342–347. doi: 10.1093/oxfordjournals.eurheartj.a059708. - DOI - PubMed
    1. Cao Y.G., Liu X.Q., Chen Y.C., Hao K., Wang G.J. Warfarin maintenance dose adjustment with indirect pharmacodynamic model in rats. Eur. J. Pharm. Scien. 2007;30:175–180. doi: 10.1016/j.ejps.2006.10.009. - DOI - PubMed
    1. Bradamante S., Barenghi L., Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc. Drug Rev. 2004;22:169–188. doi: 10.1111/j.1527-3466.2004.tb00139.x. - DOI - PubMed

Publication types

MeSH terms